Shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) rose 7.6% on Tuesday . The company traded as high as $0.75 and last traded at $0.71, approximately 915,474 shares traded hands during trading. A decline of 2% from the average daily volume of 933,134 shares. The stock had previously closed at $0.66.
MTNB has been the subject of a number of recent analyst reports. Maxim Group reaffirmed a “buy” rating and set a $5.00 target price on shares of Matinas BioPharma in a report on Thursday, May 16th. Zacks Investment Research raised Matinas BioPharma from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. BTIG Research initiated coverage on Matinas BioPharma in a report on Friday, May 17th. They set a “buy” rating and a $5.00 target price for the company. Finally, HC Wainwright initiated coverage on Matinas BioPharma in a report on Wednesday, June 26th. They set a “buy” rating and a $4.00 target price for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $4.00.
Matinas BioPharma (NYSEAMERICAN:MTNB) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.01).
Hedge funds and other institutional investors have recently modified their holdings of the company. D. E. Shaw & Co. Inc. purchased a new stake in Matinas BioPharma in the fourth quarter worth approximately $26,000. IPG Investment Advisors LLC boosted its stake in Matinas BioPharma by 54.5% in the first quarter. IPG Investment Advisors LLC now owns 42,500 shares of the company’s stock worth $46,000 after buying an additional 15,000 shares in the last quarter. Brighton Jones LLC purchased a new stake in Matinas BioPharma in the first quarter worth approximately $55,000. Wells Fargo & Company MN boosted its stake in Matinas BioPharma by 297.2% in the second quarter. Wells Fargo & Company MN now owns 103,274 shares of the company’s stock worth $88,000 after buying an additional 77,274 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Matinas BioPharma by 18.9% in the fourth quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock worth $109,000 after buying an additional 29,072 shares in the last quarter.
Matinas BioPharma Company Profile (NYSEAMERICAN:MTNB)
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
Read More: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.